The addition of bevacizumab to currently available treatment options for metastatic colorectal cancer has changed the traditional chemotherapy-based paradigm. In this review we cover published clinical trials pertaining to the toxicity and efficacy of bevacizumab for metastatic colorectal cancer. Several randomized trials have studied combinations of irinotecan, oxaliplatin, 5-fluorouracil or capecitabine with bevacizumab. Efficacy in terms of progression-free survival and overall survival has been improved to varying degrees with the addition of bevacizumab. Bevacizumab’s distinctive toxicity profile has been well demonstrated in these trials, and has been shown to be manageable. However, certain patient groups, such as the elderly, may require particular toxicity considerations with bevacizumab. The optimal timing, dose and duration of bevacizumab-containing therapy have yet to be fully determined. Further randomized data, particularly for patients with potentially resectable liver metastases, are required in order to fully define the role of bevacizumab in the increasingly complex management paradigm for this disease.
Adam, R., Avisar, E., Ariche, A., Giachetti, S., Azoulay, D., Castaing, D. et al. (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol8: 347-353.
2.
Adam, R., Wicherts, D.A., de Haas, R.J., Ciacio, O., Levi, F., Paule, B. et al. (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?J Clin Oncol27: 1829-1835.
3.
Chen, H.X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L. et al. (2006) Phase II multi-center trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol24: 3354-3360.
4.
Cunningham, D. and Glimelius, B. ( 1999) A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol26(1 Suppl 5): 6-12.
5.
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J. et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol18: 2938-2947.
6.
Ellis, L.M. ( 2006) Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol33(5 Suppl 10): S1-S7.
7.
Fuchs, C.S., Marshall, J. and Barrueco, J. ( 2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol26: 689-690.
8.
Fuchs, C.S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M. et al. (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol25: 4779-4786.
9.
Giantonio, B.J., Catalano, P.J., Meropol, N.J., O’Dwyer, P.J., Mitchell, E.P., Alberts, S.R. et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol25: 1539-1544.
10.
Giantonio, B.J., Levy, D.E., O’Dwyer, P.J., Meropol, N.J., Catalano, P.J. and Benson III, A.B. ( 2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol17: 1399-1403.
11.
Glusker, P., Recht, L. and Lane, B. ( 2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med354: 980-982; discussion 980-982.
12.
Gordon, M.S., Margolin, K., Talpaz, M., Sledge Jr, G.W., Holmgren, E., Benjamin, R. et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol19: 843-850.
13.
Grothey, A., Hedrick, E.E., Mass, R.D., Sarkar, S., Suzuki, S., Ramanathan, R.K. et al. (2008a) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol26: 183-189.
14.
Grothey, A., Sugrue, M.M., Purdie, D.M., Dong, W., Sargent, D., Hedrick, E. et al. (2008b) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol26: 5326-5334.
15.
Gruenberger, B., Tamandl, D., Schueller, J., Scheithauer, W., Zielinski, C., Herbst, F. et al. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol26: 1830-1835.
16.
Hapani, S., Chu, D. and Wu, S.(2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol10: 559-568.
17.
Hecht, J.R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D. et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol27: 672-680.
18.
Hochster, H.S., Hart, L.L., Ramanathan, R.K., Childs, B.H., Hainsworth, J.D., Cohn, A.L. et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol26: 3523-3529.
19.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med350: 2335-2342.
20.
Hurwitz, H.I., Yi, J., Ince, W., Novotny, W.F. and Rosen, O.(2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist14: 22-28.
21.
Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G. et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol21: 60-65.
22.
Kabbinavar, F.F., Schulz, J., McCleod, M., Patel, T., Hamm, J.T., Hecht, J.R. et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol23: 3697-3705.
23.
Kabbinavar, F.F., Wallace, J.F., Holmgren, E., Yi, J., Cella, D., Yost, K.J. et al. (2008) Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist13: 1021-1029.
24.
Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S. et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature362: 841-844.
25.
Klinger, M., Eipeldauer, S., Hacker, S., Herberger, B., Tamandl, D., Dorfmeister, M. et al. (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol35: 515-520.
26.
Kopetz, S., Hoff, P.M., Morris, J.S., Wolff, R.A., Eng, C., Glover, K.Y. et al. (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol28: 453-459.
27.
Kozloff, M., Yood, M.U., Berlin, J., Flynn, P.J., Kabbinavar, F.F., Purdie, D.M. et al. (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist14: 862-870.
28.
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G.J., Schlag, P.M., Rougier, P. et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet371: 1007-1016.
29.
Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M.B., Eng, C. et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer110: 2761-2767.
30.
Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R. et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol26: 2013-2019.
31.
Saltz, L.B., Lenz, H.J., Kindler, H.L., Hochster, H.S., Wadler, S., Hoff, P.M. et al. (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol25: 4557-4561.
32.
Scappaticci, F.A., Skillings, J.R., Holden, S.N., Gerber, H.P., Miller, K., Kabbinavar, F. et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst99: 1232-1239.
33.
Tebbutt, N.C., Wilson, K., Gebski, V.J., Cummins, M.M., Zannino, D., van Hazel, G.A. et al. (2010) Capecitabine, bevacizumab and mitomycin C in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomised phase III MAX study. J Clin Oncol, in press.
34.
Tol, J., Koopman, M., Cats, A., Rodenburg, C.J., Creemers, G.J., Schrama, J.G. et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med360: 563-572.
35.
Van Cutsem, E., Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M. et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol20: 1842-1847.
36.
Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A. and Ferrara, N. ( 1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis . J Clin Invest95: 1789-1797.
37.
Welch, S., Spithoff, K., Rumble, R.B. and Maroun, J.(2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol21: 1152-1162.
